DRDR.L vs. BTEE.L
DRDR.L (iShares Healthcare Innovation UCITS ETF USD (Acc)) and BTEE.L (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) are both Health & Biotech Equities funds from iShares - DRDR.L tracks the MSCI World/Health Care NR USD while BTEE.L tracks the NASDAQ Biotechnology TR USD. Both are passively managed. Over the past 5 years, DRDR.L returned -0.91%/yr vs 5.84%/yr for BTEE.L. Their correlation of 0.83 suggests significant overlap in exposure. DRDR.L charges 0.40%/yr vs 0.35%/yr for BTEE.L.
Performance
DRDR.L vs. BTEE.L - Performance Comparison
Loading charts...
Different Trading Currencies
DRDR.L is traded in GBp, while BTEE.L is traded in USD. To make them comparable, the BTEE.L values have been converted to GBp using the latest available exchange rates.
Returns By Period
In the year-to-date period, DRDR.L achieves a 1.01% return, which is significantly lower than BTEE.L's 5.01% return.
DRDR.L
- 1D
- 3.48%
- 1M
- 6.16%
- YTD
- 1.01%
- 6M
- -0.48%
- 1Y
- 21.74%
- 3Y*
- 3.43%
- 5Y*
- -0.91%
- 10Y*
- —
BTEE.L
- 1D
- 3.30%
- 1M
- 2.09%
- YTD
- 5.01%
- 6M
- 2.46%
- 1Y
- 42.82%
- 3Y*
- 10.28%
- 5Y*
- 5.84%
- 10Y*
- —
DRDR.L vs. BTEE.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
DRDR.L iShares Healthcare Innovation UCITS ETF USD (Acc) | 1.01% | 10.25% | 2.62% | -2.51% | -14.93% | -5.21% | 48.69% | 8.88% | -6.06% |
BTEE.L iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 5.01% | 23.36% | 0.03% | 0.55% | -1.41% | 0.37% | 23.80% | 20.78% | -7.80% |
Correlation
The correlation between DRDR.L and BTEE.L is 0.82, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.82 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.83 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.82 |
Correlation (All Time) Calculated using the full available price history since Mar 9, 2018 | 0.83 |
The correlation between DRDR.L and BTEE.L has been stable across timeframes, ranging from 0.82 to 0.83 - a consistent structural relationship.
DRDR.L vs. BTEE.L - Sectors Allocation Comparison
Sectors
DRDR.L
BTEE.L
Healthcare
Technology
-
Industrials
-
Basic Materials
-
Financial Services
-
Consumer Defensive
-
Communication Services
-
-
Consumer Cyclical
-
-
Energy
-
-
Real Estate
-
-
Utilities
-
-
Healthcare
DRDR.L
BTEE.L
Technology
DRDR.L
BTEE.L
-
Industrials
DRDR.L
BTEE.L
-
Basic Materials
DRDR.L
BTEE.L
-
Financial Services
DRDR.L
BTEE.L
-
Consumer Defensive
DRDR.L
BTEE.L
-
Communication Services
DRDR.L
-
BTEE.L
-
Consumer Cyclical
DRDR.L
-
BTEE.L
-
Energy
DRDR.L
-
BTEE.L
-
Real Estate
DRDR.L
-
BTEE.L
-
Utilities
DRDR.L
-
BTEE.L
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
DRDR.L vs. BTEE.L — Risk / Return Rank
DRDR.L
BTEE.L
DRDR.L vs. BTEE.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Healthcare Innovation UCITS ETF USD (Acc) (DRDR.L) and iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| DRDR.L | BTEE.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.78 | ||
| Sortino ratioReturn per unit of downside risk | -0.92 | ||
| Omega ratioGain probability vs. loss probability | 1.24 | 1.36 | -0.12 |
| Calmar ratioReturn relative to maximum drawdown | 1.73 | 6.09 | -4.36 |
| Martin ratioReturn relative to average drawdown | 4.35 | 17.42 | -13.06 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| DRDR.L | BTEE.L | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.39 | 2.17 | -0.78 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.05 | 0.28 | -0.33 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.34 | 0.32 | +0.02 |
Drawdowns
DRDR.L vs. BTEE.L - Drawdown Comparison
The maximum DRDR.L drawdown since its inception was -38.49%, which is greater than BTEE.L's maximum drawdown of -30.88%. Use the drawdown chart below to compare losses from any high point for DRDR.L and BTEE.L.
Loading charts...
Drawdown Indicators
| DRDR.L | BTEE.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -38.49% | -30.88% | -7.61% |
Max Drawdown (1Y)Largest decline over 1 year | -12.51% | -7.00% | -5.51% |
Max Drawdown (3Y)Largest decline over 3 years | -22.38% | -26.47% | +4.09% |
Max Drawdown (5Y)Largest decline over 5 years | -35.81% | -30.88% | -4.93% |
Current DrawdownCurrent decline from peak | -16.88% | -1.76% | -15.12% |
Average DrawdownAverage peak-to-trough decline | -15.17% | -10.12% | -5.05% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.98% | 2.45% | +2.53% |
Volatility
DRDR.L vs. BTEE.L - Volatility Comparison
The current volatility for iShares Healthcare Innovation UCITS ETF USD (Acc) (DRDR.L) is 4.79%, while iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) (BTEE.L) has a volatility of 7.01%. This indicates that DRDR.L experiences smaller price fluctuations and is considered to be less risky than BTEE.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| DRDR.L | BTEE.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 4.79% | 7.01% | -2.22% |
Volatility (6M)Calculated over the trailing 6-month period | 11.52% | 15.10% | -3.58% |
Volatility (1Y)Calculated over the trailing 1-year period | 15.56% | 19.60% | -4.04% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 17.52% | 20.72% | -3.20% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 18.58% | 22.42% | -3.84% |
DRDR.L vs. BTEE.L - Expense Ratio Comparison
DRDR.L has a 0.40% expense ratio, which is higher than BTEE.L's 0.35% expense ratio.
Dividends
DRDR.L vs. BTEE.L - Dividend Comparison
DRDR.L has not paid dividends to shareholders, while BTEE.L's dividend yield for the trailing twelve months is around 0.36%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
BTEE.L iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.36% | 0.37% | 0.46% | 0.39% | 0.44% | 0.25% | 0.17% | 0.14% | 0.07% |
DRDR.L iShares Healthcare Innovation UCITS ETF USD (Acc) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Frequently Asked Questions
DRDR.L and BTEE.L have a correlation of 0.82, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, BTEE.L is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.
BTEE.L is cheaper with a 0.35% expense ratio, compared with 0.40% for DRDR.L.
DRDR.L tracks MSCI World/Health Care NR USD, while BTEE.L tracks NASDAQ Biotechnology TR USD. Their fees differ too: 0.40% for DRDR.L and 0.35% for BTEE.L.
Find the right allocation for DRDR.L and BTEE.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer